Morgan Stanley has increased its first quarter estimates for Hospira HSP.
According to the report, “We are increasing our 1Q EPS estimate to $0.79 from $0.65 and revenues from $893MM to $939MM more or less in-line with the updated guidance. For the full year, our EPS estimate rises to $4.00 from $3.96 as we shift generic Taxotere revenues and EPS into 1Q with modest upside to our market share assumptions for the full year.”
HSP closed at $54.01 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in